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ABSTRACT
Objective: Numerous studies have reported that
chronic obstructive pulmonary disease or impaired
lung function are associated with later coronary heart
disease (CHD). However, it is unclear if lung function
is an independent risk factor, as many of these studies
have included only limited measures of other factors
associated with CHD.
Methods: In total 2167 men of all ages in the first
Northwick Park Heart Study were followed for a median
of 30 years. Cox regression models were used to
assess the relationship between peak flow rate (PFR)
and CHD mortality adjusted for potential confounders
measured at baseline. Analyses allowed for missing
data, and secondary analyses for repeat measures on
some men and competing risks of CHD death.
Results: There were 254 CHD deaths with some
evidence of an association between PFR and CHD
mortality. The adjusted HRs (95% CIs) from the lowest
to the highest of four PFR quartiles were 1.53 (1.04 to
2.25), <430 L/min; 1.43 (0.99 to 2.08), 430 – <490 L/min;
and 1.31 (0.93 to 1.86), 490 – <550 L/min; compared
with the reference group of ≥550 L/min (trend test
p=0.025). Other associations with CHD mortality were
observed for systolic blood pressure (p<0.0001), body
mass index (p=0.0002), smoking status (p=0.015),
blood cholesterol (p=0.005), plasma fibrinogen
(p=0.001) and high-risk ECG (p=0.021). There were
no strong associations for factors V and VIII or
platelet count.
Conclusions: After allowing for a range of other risk
factors associated with CHD, there was only limited
evidence of a relation between PFR and CHD mortality.
INTRODUCTION
There have been many reports that chronic
obstructive pulmonary disease (COPD) or
measures found in impaired pulmonary
function such as peak ﬂow rate (PFR) or
forced expiratory volume (FEV) are asso-
ciated with coronary heart disease (CHD)
events.1–16 Consequently, impaired respira-
tory function is generally considered as a risk
factor for CHD. Results similar to those for
CHD have been reported for stroke.17 18
Associations between respiratory function
with the development of carotid
atherosclerotic plaques19 and with central
arterial stiffness have also been described.
This report uses PFR as an index of respira-
tory function to assess the relationship with
CHD mortality. The study’s ﬁrst advantage is
that the results presented include data on
some variables in the coagulation system inﬂu-
encing the thrombotic component of CHD
that have not previously been reported in rela-
tion to PFR and COPD. Second, analyses of
results have included methods to allow for
imputation of missing values and also consid-
eration of competing risks of non-CHD
deaths. Third, repeat measurements have
enabled assessments of the effects of changes
over time using time-updated modelling tech-
niques. Finally, participants have been fol-
lowed up for a median duration of 30 years,
so that the value or otherwise of data on PFR
and CHD mortality over a longer time period
than in other studies has been possible.
METHODS
This report is based on data from the ﬁrst
Northwick Park Heart Study (NPHS-1). Full
details have been reported elsewhere.20
KEY MESSAGES
What is already known about this subject?
▸ Impaired lung function is thought to be a risk
factor for coronary heart disease.
What does this study add?
▸ While there is evidence of an association
between respiratory function and coronary heart
disease it is unlikely to be a strong risk factor.
How might this impact on clinical practice?
▸ It is important to deal with impaired respiratory
function but it is unlikely to impact strongly on
the risk of coronary heart disease to the extent
suggested by other studies which indicated a
doubling in the risk whereas our study, after
adjusting for a range of risk factors, indicates an
increased risk of approximately 40%.
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Participants
Between 1972 and 1978, NPHS-I recruited men of all
ages working at three industrial or occupational sites in
North West London. The response to invitations to par-
ticipate was about 80%. Methods for the clinical examin-
ation, laboratory measurements and clotting factor
assays and follow-up have been described before.20
Follow-up for non-fatal events ended in 1986. However,
follow-up for fatal events, with which this report is con-
cerned, continued until June 2006, with notiﬁcations of
deaths and their causes having been provided through-
out the study by the Ofﬁce for National Statistics. Blind
assessments of causes of death have been made as
before,20 based on information from general practi-
tioners, hospitals and coroners.
As in previous reports of men in the NPHS-1 study,
analyses are conﬁned to white participants who had not
previously had myocardial infarcts (but including 78
men with a history of deﬁnite or possible angina).20
Most men (1703/2167; 78%) had repeat blood samples
taken at follow-up examinations between 1978 and 1984,
at a median of 6.5 years after entry to the study.
Comparison of baseline values for those who were or
were not available for follow-up (excluding the 81 men
who died within 6.5 years of entry to the study in order
to include only those potentially available for follow-up)
showed the former to be on average 4 years older, to use
less alcohol and to have higher mean body mass index
(BMI), blood cholesterol, red blood cell count, haemo-
globin and packed cell volumes than those not followed
up. Those not followed had lower age-adjusted all-cause
mortality and similar CHD mortality compared with
those followed up. Bearing these differences in mind, it
has been possible to establish prospective data on the
impact of PFR on cardiac mortality over time, using
time-updated models to take account of the repeat mea-
surements made.
Measurements
With participants standing up, PFR was measured three
times using the original Wright peak ﬂow metre. The
clinic nurse gave instructions on what was required, with
a demonstration of the appropriate respiratory effort.
With a brief rest interval between each of the three mea-
sures, the highest of these was recorded. Besides PFR
itself and age and gender, characteristics recorded20
included smoking status, alcohol use, height and weight
and hence BMI, blood pressure (average of three read-
ings), social class, total cholesterol and triglycerides
(fasting), and automated Coulter full blood count
(details shown or noted in tables). Biological activities of
clotting factors V, VII and VIII were assayed,21–23 and
ﬁbrinogen was measured by a clot weight method.24 Of
the clotting factors, only results for factor VII and
ﬁbrinogen are shown, as those for V and VIII were not
associated with CHD, although they were included in
the statistical models to allow as fully as possible for any
confounding effect on the relationship between PFR
and CHD. ECG ﬁndings were coded according to the
Minnesota code,25 and classiﬁed as indicating higher or
lower risk of CHD according to the groupings estab-
lished, and successfully validated, for the Medical
Research Council (MRC) Hypertension Trial.26
NPHS-1 started in 1972, which was before the develop-
ment of ethics committees in the UK. It was therefore
not submitted to ethics committees. Those approached
about the study were given a full verbal explanation of
the reasons for it, its nature and what it would involve,
and agreed to take part.
Statistical analyses
PFR was considered in four categories: (1) <430 L/min
(2) 430–<490 L/min (3) 490–<550 L/min and (4)
≥550 L/min. These categories were deﬁned to include
approximately a quarter of the CHD deaths in each.
PFR was categorised in this way as there was no observed
association between PFR and CHD mortality at higher
levels of PFR. The characteristics of the patients at base-
line and also for those who were followed up have been
tabulated, and CHD death rates calculated. The primary
analysis has focused on the association of PFR measured
at baseline with CHD death, using Cox regression
models. Unadjusted HRs for PFR were estimated in
order to compare with adjusted HRs, and Kaplan-Meier
curves showing the cumulative percentage of CHD
death by PFR groups have been presented. All other
analyses have been adjusted for age by setting the time-
scale in the Cox models to be current age, while also
including age at baseline to allow that baseline
characteristics may have been measured several years
previously.27 A Cox regression model was developed for
the primary analysis to allow for the confounding effect
of other potential risk factors collected at baseline.
Covariates of interest were included irrespective of the
strength of evidence for their association with CHD mor-
tality to more fully allow for any potential confounding
due to these covariates. Data were missing for some vari-
ables, particularly for some of the laboratory measure-
ments, although the numbers were low for baseline data
(<5% for any one variable), being higher for follow-up
data (<12%). In order to adjust for these missing data,
multiple imputation techniques with chained equations
were used, assuming missingness is at random, with 100
imputations using all covariates in the model including
the outcome variable of CHD mortality and time in the
study.28 Analyses were also conducted using a complete-
case analysis (ie, those with values for all variables) and
by imputing the median value for missing covariates to
assess whether results were consistent with the ﬁndings
from the primary analysis.
In order to assess whether the impact of PFR changed
according to time in the study or with age, multivariable
Cox models were ﬁtted with interaction terms between
PFR and (1) time in follow-up (≤15 or >15 years) or (2)
current age (≤75 or >75 years) after ﬁrst splitting the
data according to the relevant timescales.
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Table 1 Characteristics and cardiac mortality of individuals at baseline and follow-up
Characteristic
Baseline Follow-up
Cardiac
death
Non cardiac
death Total
Cardiac
death
Non cardiac
death
Total N (rate)* N* N N (rate)* N*
Total 2167 254 (4.58) 1913 1703 192 (5.65) 1511
Peak flow rate (L/min)
<430 316 57 (8.45) 259 346 50 (8.21) 296
430–<490 385 60 (6.57) 325 311 43 (7.12) 268
490–<550 584 71 (4.62) 513 401 41 (4.99) 360
≥550 878 66 (2.73) 812 559 42 (3.42) 517
Missing 4 86
Mean (SD) 493 (90) 525 (91) 473 (109) 506 (102)
Age (years)
<45 864 26 (1.01) 838 392 3 (0.31) 389
45–49 352 30 (3.13) 322 188 12 (2.85) 176
50–54 346 60 (7.22) 286 295 25 (3.94) 270
55–59 353 73 (9.61) 280 283 44 (8.09) 239
≥60 252 65 (15.53) 187 545 108 (12.94) 437
Missing 0 0
Mean (SD) 54.7 (7.1) 45.2 (12.2) 60.6 (7.1) 52.4 (11.5)
ECG
Low risk 1966 215 (4.22) 1751 1410 132 (4.54) 1278
High risk 201 39 (8.46) 162 293 60 (12.19) 233
Missing 0 0
Previous angina
No 2093 232 (4.30) 1861 1600 165 (5.11) 1435
Yes 74 22 (14.54) 52 103 27 (15.61) 76
Missing 0 0
Smoking status
Never 575 38 (2.37) 537 427 30 (3.23) 397
Ex-smoker 544 72 (5.24) 472 604 72 (6.13) 532
Current smoker 1048 144 (5.59) 904 672 90 (6.95) 582
Missing 0 0
Body mass index (kg/m2)
<22.5 409 20 (1.85) 389 237 17 (3.47) 220
22.5–<25 702 63 (3.39) 639 497 47 (4.65) 450
25–<27.5 648 88 (5.43) 560 516 53 (5.05) 463
27.5–<30 282 55 (7.94) 227 259 36 (7.03) 223
≥30 124 27 (9.12) 97 116 23 (10.42) 93
Missing 2 78
Mean (SD) 26.3 (3.0) 24.9 (3.0) 26.4 (3.2) 25.4 (3.1)
Systolic blood pressure (mm Hg)
<140 1154 82 (2.60) 1072 768 38 (2.27) 730
140–<160 652 79 (4.87) 573 532 67 (6.32) 465
160–<180 247 55 (9.89) 192 255 47 (10.52) 208
≥180 111 38 (18.09) 73 137 40 (20.03) 97
Missing 3 11
Mean (SD) 153 (26) 137 (21) 160 (25) 143 (22)
Cholesterol (mmol/L)
<5 403 22 (1.97) 381 284 16 (2.72) 268
5–<6 695 62 (3.42) 633 545 49 (4.39) 496
6–<7 584 78 (5.40) 506 431 63 (7.27) 368
≥7 365 79 (9.02) 286 242 33 (6.92) 209
Missing 120 201
Mean (SD) 6.48 (1.23) 5.85 (1.15) 6.25 (1.06) 5.86 (1.11)
Factor VII (% of standard)
<90 540 38 (2.58) 502 270 20 (3.51) 250
90–<110 675 69 (3.94) 606 491 46 (4.66) 445
110–<130 479 69 (5.88) 410 458 57 (6.15) 401
Continued
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A secondary analysis was also conducted using infor-
mation for those in whom a follow-up visit was con-
ducted (acknowledging, as already indicated, that those
followed up may not have been truly representative of
the initial population studied). Time-updated Cox
models accounting for repeat measurements of variables
for those in whom a follow-up visit was conducted were
used to consider age-adjusted and more fully adjusted
HRs.
Finally, an analysis was conducted to consider whether
there was any impact of competing risks due to deaths
from non-cardiac causes using the method of Fine and
Gray29 for competing risks regression.
All analyses were conducted using Stata V.13.0
(StataCorp. 2013. Stata Statistical Software: Release 13.
College Station, Texas, USA: StataCorp LP).
RESULTS
In total, data for 2167 men were included in the ana-
lyses, and the men were followed for a median of
30 years. Table 1 shows that there were 254 cardiac
deaths (rate 4.58/1000 person-years). In addition, 720
men died of non-cardiac causes over the follow-up
period. Table 1 also shows that, as expected, advancing
age is strongly associated with increasing HRs for CHD
death. The unadjusted HRs increase with decreasing
PFR (ﬁgure 1), although after adjustment for age the
HRs move towards 1 (table 2). Table 2 gives results from
the multivariable model and shows that after adjusting
for age and other risk factors measured at baseline,
including BMI and smoking, the impact of PFR on CHD
is reduced further. The hazard for the lowest PFR quar-
tile is 54% more than for the highest quartile, although
the evidence for an association, though suggestive, is not
strong (trend test p=0.025). There was an increased risk
of CHD mortality with smoking, BMI, systolic blood
pressure, cholesterol, ﬁbrinogen and an abnormal ECG
considered high risk by the Minnesota coding. NPHS-1
has not previously included results based on ECG data,
and our results now show that ‘high-risk’ abnormalities
are associated with increased CHD mortality, HR 1.58
(95% CI 1.11 to 2.27). The association of factor VII with
CHD mortality is of marginal statistical signiﬁcance
(p=0.058). Other factors included in this analysis but
with little evidence for an association with cardiac death
were triglycerides, haemoglobin, red blood cell count,
white blood cell count or packed cell volume (data not
Table 1 Continued
Characteristic
Baseline Follow-up
Cardiac
death
Non cardiac
death Total
Cardiac
death
Non cardiac
death
Total N (rate)* N* N N (rate)* N*
≥130 379 69 (7.62) 310 290 38 (6.57) 252
Missing 94 194
Mean (SD) 117 (30) 106 (26) 115 (22) 111 (24)
Fibrinogen (g/L)
<2.5 565 37 (2.32) 528 264 14 (2.34) 250
2.5–<3 652 67 (3.89) 585 494 38 (3.58) 456
3–<3.5 512 62 (4.94) 450 397 52 (6.74) 343
3.5–<4 217 49 (10.12) 168 222 34 (8.36) 188
≥4 126 28 (11.20) 98 132 24 (10.75) 108
Missing 95 194
Mean (SD) 3.18 (0.71) 2.87 (0.65) 3.29 (0.64) 3.05 (0.67)
*Unless otherwise stated. Rates are per 1000 person-years.
Figure 1 Kaplan-Meier curve of cumulative percentage of
cardiac mortality by peak flow rate category (adjusted HRs
(95% CI) compared with ≥550 L/min: (<430 L/min) 1.53
(1.04 to 2.25); (430 – <490 L/min) 1.43 (0.99 to 2.08);
(490 – <550 L/min) 1.31 (0.93 to 1.86)).
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shown though referred to in table 2). Neither alcohol
use nor social class appeared to be independent risk
factors. There was no evidence that the association
between PFR and CHD mortality changed over time of
follow-up (interaction p value 0.79) or with age (inter-
action p=0.24).
In the secondary analysis using updated values for
those in whom a follow-up visit was available, table 3
shows that the association of PFR with CHD mortality
was less than for those with baseline values (trend test
p=0.50), though the hazard was 15% higher in the
lowest quartile of PFR than in the highest quartile
(≥550 L/min). There was no evidence for an association
of factor VII with CHD mortality, whereas the impact of
a ‘high-risk’ ECG abnormality was stronger than when
considering baseline ECG alone.
Further analyses considered complete-case analyses
only, and also by imputation of the median values of
missing variables. Results were largely consistent with
those shown. Finally, an analysis was undertaken allowing
for the potential competing risk of non-cardiac mortality
and results were again consistent with the results pre-
sented (results not shown).
DISCUSSION
The prospective studies that have included measures of
impaired lung function such as PFR, FEV or FEV1 and
that have shown an association with the incidence of
fatal CHD have come from many settings, often the
USA,4 5 7 10 but also from the UK and other European
countries,2 6 8 12 14 China,11 15 Australia and New
Zealand,9 and India.13 Some have collected data from
more than one country.1 3 Many studies have typically
reported relative risks (RRs) of 2 or less for the associ-
ation between measures of impaired lung function and
CHD, though in two North American studies,7 risks up
to 4 were recorded. A systematic review of the relation-
ship between FEV1 and cardiovascular mortality
reported a pooled RR of 1.75 comparing those in the
lowest quintile to the highest quintile of FEV1.
16 In
NPHS-1, the apparent effect of PFR on CHD, showing a
HR difference of 53% between the lowest and highest
quartiles, was modest using baseline characteristics (ie,
analysis based on all participants) and had largely disap-
peared based on those who had follow-up examinations.
There do not appear to be large or consistent differ-
ences between FEV, FEV1 and PFR that would affect the
Table 2 Multivariable associations with cardiac mortality using baseline characteristics
Age-adjusted Fully adjusted*
HR 95% CI HR 95% CI p Value
Peak flow rate (L/min)†
<430 1.54 1.07 to 2.21 1.53 1.04 to 2.25 0.025‡
430–<490 1.40 0.98 to 2.00 1.43 0.99 to 2.08
490–<550 1.30 0.93 to 1.81 1.31 0.93 to 1.86
≥550 1 – 1 –
Systolic blood pressure
Per 10 mm Hg increase 1.18 1.12 to 1.24 1.13 1.07 to 1.19 <0.0001
Body mass index
Per kg/m2 increase 1.11 1.06 to 1.15 1.09 1.04 to 1.14 0.0002
Smoking status
Non-smoker 1 – 1 – 0.015‡
Ex-smoker 1.24 0.84 to 1.85 1.04 0.70 to 1.56
Current smoker 1.61 1.13 to 2.31 1.51 1.02 to 2.24
Previous angina
No 1 – 1 – 0.010
Yes 2.11 1.36 to 3.27 1.83 1.16 to 2.90
Cholesterol
Per mmol/L increase 1.29 1.17 to 1.43 1.18 1.05 to 1.33 0.005
Fibrinogen (g/L)
≤3.5 1 – 1 – 0.001‡
>3.5–4 1.78 1.29 to 2.46 1.44 1.03 to 2.03
>4 1.91 1.25 to 2.89 1.91 1.22 to 2.98
Factor VII (% of standard)
Per 10 unit increase 1.10 1.05 to 1.14 1.05 1.00 to 1.10 0.058
ECG
Low risk 1 – 1 – 0.021
High risk 1.74 1.23 to 2.45 1.52 1.07 to 2.19
*Also adjusted for age, triglycerides, platelets, white blood cell count, red blood cell count, haemoglobin, packed cell volume, alcohol use,
social class, factor V and factor VIII.
†Unadjusted HRs for peak flow rate are 3.33 (<430), 2.51 (430–<490) and 1.70 (490–<550) compared with ≥550 L/min.
‡Trend test across groups.
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ﬁndings of epidemiological studies. A study of older par-
ticipants in east Boston5 also used only PFR, and gave
much the same results as ours and as those for other
studies (differences may be important in assessing lung
function in clinical settings, such as acute asthma attacks
in children.)
Data for men who had previously had major CHD
events were not included in the analyses. However,
abnormal ECGs often reﬂecting early pathological
changes of CHD were, not surprisingly, signiﬁcantly asso-
ciated with CHD mortality. Omission of ECG data from
other studies may thus well account for the generally
stronger associations of PFR and other measures of
impaired lung function with CHD than in NPHS–1,
since these other studies have not been in a position to
allow for the early pathology of CHD and the correlation
of PFR with ECG ﬁndings. Smoking, cholesterol and sys-
tolic blood pressure were other independent risk factors
associated with CHD death. We are aware of only one
other study that has included measurement of plasma
ﬁbrinogen, which increases with the level of smoking
but remains a strong independent risk factor for CHD.
However, this study,30 CARDIA, dealt mainly with the
association of ﬁbrinogen with risk factors including
COPD that contribute to CHD, rather than prospective
associations with CHD itself.
In the present study, the association of plasma ﬁbrino-
gen with fatal CHD was highly statistically signiﬁcant in
the multivariable analysis (table 2), which takes account
of correlations between different risk factors. An explan-
ation might be the contribution of ﬁbrinogen to throm-
bosis in CHD, or as a marker of the degree of an
inﬂammatory process in COPD and CHD. The trend
was similar but reduced in the time-updated model
(table 3), although there was little evidence for an asso-
ciation. There was a suggestion that factor VII may be
associated with CHD in the multivariable model using
baseline data, and may thus have contributed to the
thrombotic element in CHD, though the ﬁnding was at
a marginal level and there was no association in the
time-updated model. There was no evidence that factors
V and VIII and platelet count (as other components of
the haemostatic system) were associated with fatal CHD.
The Whitehall Cohort II study concluded that socio-
economic differences were not important in explaining
the association between lung function and mortality.12
Table 3 Multivariable associations with cardiac mortality using time-updated model
Age-adjusted Fully adjusted*
HR 95% CI HR 95% CI p Value
Peak flow rate (L/min)†
<430 1.36 0.94 to 1.97 1.15 0.77 to 1.70 0.50‡
430–<490 1.21 0.83 to 1.77 1.10 0.74 to 1.64
490–<550 1.06 0.73 to 1.55 1.07 0.73 to 1.58
≥550 1 – 1 –
Systolic blood pressure
Per 10 mm Hg increase 1.20 1.14 to 1.26 1.17 1.11 to 1.23 <0.0001
Body mass index
Per kg/m2 increase 1.08 1.04 to 1.12 1.06 1.01 to 1.10 0.015
Smoking status
Non-smoker 1 – 1 – 0.018‡
Ex-smoker 1.18 0.80 to 1.73 0.98 0.66 to 1.45
Current smoker 1.74 1.21 to 2.51 1.50 0.99 to 2.25
Previous angina
No 1 – 1 – 0.001
Yes 2.05 1.41 to 2.97 1.93 1.31 to 2.83
Cholesterol
Per mmol/L increase 1.31 1.17 to 1.47 1.22 1.07 to 1.38 0.003
Fibrinogen (g/L)
≤3.5 1 – 1 – 0.16‡
>3.5–4 1.37 0.98 to 1.92 1.04 0.73 to 1.48
>4 1.82 1.26 to 2.63 1.37 0.92 to 2.04
Factor VII (% of standard)
Per 10 unit increase 1.07 1.03 to 1.13 1.03 0.98 to 1.09 0.22
ECG
Low risk 1 – 1 – <0.0003
High risk 2.04 1.55 to 2.68 1.71 1.28 to 2.28
*Also adjusted for age, triglycerides, platelets, white blood cell count, red blood cell count, haemoglobin, packed cell volume, alcohol use,
social class, factor V and factor VIII.
†Unadjusted HRs for peak flow rate are 3.18 (<430), 2.37 (430–<490) and 1.76 (490–<550) compared with ≥550 L/min.
‡Trend test across groups.
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Virtually all prospective studies are missing data for
some variables. Long-term follow-up periods almost inevit-
ably mean that their data will be subject to competing
risks of non-cardiac mortality. However, few allow for
these points. We have used well-tested and accepted
methods of imputation to allow for missing values in our
data, and the results were similar compared with the ana-
lyses not using these methods. Allowance for competing
risks of non-CHD mortality also made little difference.
Treatment of COPD appears to reduce the onset of
cardiovascular disease.31 However, Lange et al6 con-
cluded that “although impaired ventilatory function is a
signiﬁcant predictor of death from myocardial infarction
and other cardiovascular diseases, it should not be
regarded as a genuine risk factor for ischaemic heart
disease.” We would agree with this view, in that the inclu-
sion of a wide range of characteristics associated with
CHD, including ﬁbrinogen and abnormal ECG ﬁndings,
suggests that measures such as PFR are not strongly and
independently associated with fatal CHD, and that the
view that they usefully predict CHD should be modiﬁed
accordingly.
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